{
    "ticker": "LPTX",
    "name": "Leap Therapeutics, Inc.",
    "description": "Leap Therapeutics, Inc. is a biopharmaceutical company focused on developing novel therapeutics to treat cancer. Founded in 2015 and headquartered in Cambridge, Massachusetts, Leap is dedicated to advancing the field of oncology through innovative approaches. The company's lead product candidates are designed to target specific pathways involved in cancer progression and resistance, aiming to improve patient outcomes through precision medicine. Leap's flagship drug, DKN-01, is an anti-DKK1 monoclonal antibody currently in clinical trials for various cancer indications, including gastric and other solid tumors. The company is also exploring partnerships and collaborations to enhance its research and development capabilities. With a strong emphasis on scientific excellence and patient-centric approaches, Leap Therapeutics aims to make significant contributions to the treatment of cancer and enhance the quality of life for patients around the world.",
    "industry": [
        "Biotechnology",
        "Pharmaceuticals"
    ],
    "headquarters": "Cambridge, Massachusetts, USA",
    "founded": "2015",
    "website": "https://www.leaptx.com",
    "ceo": "Robert A. J. B. R. T. S. S. D. S. K. P. D.",
    "social_media": {
        "twitter": "https://twitter.com/leaptherapeutics",
        "linkedin": "https://www.linkedin.com/company/leap-therapeutics/"
    },
    "investor_relations": "https://ir.leaptx.com",
    "key_executives": [
        {
            "name": "Robert A. J. B. R. T. S. S. D. S. K. P. D.",
            "position": "CEO"
        },
        {
            "name": "Laura M. H. S. B.",
            "position": "CFO"
        }
    ],
    "product_categories": [
        {
            "category": "Oncology Drug Candidates",
            "products": [
                "DKN-01"
            ]
        }
    ],
    "seo": {
        "meta_title": "Leap Therapeutics, Inc. | Innovating Cancer Therapies",
        "meta_description": "Leap Therapeutics, Inc. is focused on developing novel therapeutics for cancer treatment, with a commitment to improving patient outcomes through precision medicine.",
        "keywords": [
            "Leap Therapeutics",
            "Biotechnology",
            "Cancer Treatment",
            "DKN-01",
            "Pharmaceuticals",
            "Oncology"
        ]
    },
    "faq": [
        {
            "question": "What does Leap Therapeutics focus on?",
            "answer": "Leap Therapeutics focuses on developing novel therapeutics for cancer treatment."
        },
        {
            "question": "What is the lead product candidate of Leap Therapeutics?",
            "answer": "The lead product candidate is DKN-01, an anti-DKK1 monoclonal antibody."
        },
        {
            "question": "Where is Leap Therapeutics headquartered?",
            "answer": "Leap Therapeutics is headquartered in Cambridge, Massachusetts, USA."
        },
        {
            "question": "When was Leap Therapeutics founded?",
            "answer": "Leap Therapeutics was founded in 2015."
        }
    ],
    "competitors": [
        "NVO",
        "AMGN",
        "BMY",
        "REGN"
    ],
    "related_stocks": [
        "GILD",
        "VRTX",
        "ABBV",
        "MRNA"
    ]
}